论文部分内容阅读
目的:探讨乙肝疫苗接种者和隐性感染康复者血清体外阻断HBV感染作用的差异。方法:雅培ELISA定量测定乙肝疫苗接种应答者和隐性HBV感染康复者血清乙肝表面抗体,再调整到相同含量,分别和HBV预孵育1 h后感染Hep G2细胞,24 h后巢式PCR检测Hep G2细胞中HBV-DNA,评估其阻断效应。结果:同等浓度下,隐性感染康复者和乙肝疫苗接种者血清对野生株HBV感染阻断作用无差异,但乙肝疫苗接种者血清对变异株无阻断效应,隐性感染康复者对变异株仍有阻断作用,其作用明显弱于野生株。结论:隐性感染康复者血清对野生株和变异株HBV均有阻断作用,而乙肝疫苗接种者血清对变异株无阻断效应,提示新型乙肝疫苗应包含更多抗原成分如前S1/S2抗原,以对HBV变异株产生中和效应,应用多种成分的抗乙肝免疫球蛋白阻断肝移植后变异株HBV再感染十分重要。
Objective: To explore the difference between the effects of blocking the serum HBV infection in vitro by hepatitis B vaccinees and those with latent infection. Methods: Abbott ELISA was used to measure the serum HBsAg in hepatitis B vaccination responders and latent HBV infection survivors, and then adjusted to the same level. Hep G2 cells were infected with HBV pre-incubated for 1 h. After 24 h, nested PCR was used to detect Hep G2 cells in HBV-DNA, to assess its blocking effect. Results: In the same concentration, serums from patients with latent infection and hepatitis B vaccine did not show any significant difference in blocking HBV infection among wild-type strains, but serum from hepatitis B vaccine-vaccinated patients did not block the mutation. There is still a blocking effect, its role was significantly weaker than wild strains. CONCLUSIONS: Serum of patients with latent infection has a blocking effect on both the wild-type and variant HBV strains, while the serum of hepatitis B vaccine-vaccinated patients has no blocking effect on the mutant strains, suggesting that the new hepatitis B vaccine should contain more antigenic components such as the former S1 / S2 Antigen in order to neutralize the effect of HBV variant strains, the application of multiple components of anti-hepatitis B immunoglobulin blocking HBV re-infection after liver transplantation is very important.